Thomas Smith
Stock Analyst at Leerink Partners
(2.28)
# 2,688
Out of 5,030 analysts
68
Total ratings
29.03%
Success rate
14.21%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Thomas Smith
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RAPT RAPT Therapeutics | Upgrades: Outperform | $16 → $37 | $29.34 | +26.11% | 3 | Sep 26, 2025 | |
| EQ Equillium | Downgrades: Market Perform | $3 → $1 | $1.46 | -31.51% | 4 | Mar 28, 2025 | |
| QTTB Q32 Bio | Downgrades: Market Perform | $68 → $9 | $3.17 | +183.91% | 2 | Dec 11, 2024 | |
| ACRS Aclaris Therapeutics | Upgrades: Outperform | $2 → $7 | $1.90 | +268.42% | 7 | Nov 19, 2024 | |
| ALMS Alumis | Initiates: Outperform | $29 | $4.49 | +545.88% | 1 | Jul 23, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Outperform | $39 | $8.99 | +333.77% | 1 | Apr 23, 2024 | |
| SGMT Sagimet Biosciences | Initiates: Outperform | $26 | $7.36 | +253.26% | 1 | Mar 25, 2024 | |
| ABVX ABIVAX Société Anonyme | Initiates: Outperform | $20 | $92.73 | -78.43% | 1 | Nov 14, 2023 | |
| ARGX argenx SE | Maintains: Outperform | $430 → $435 | $843.66 | -48.44% | 3 | Mar 3, 2023 | |
| IRON Disc Medicine | Initiates: Outperform | $36 | $89.94 | -59.97% | 1 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $7 | $1.73 | +304.62% | 4 | Feb 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $21 | $17.51 | +19.93% | 6 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $45 | $24.21 | +85.87% | 2 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $6 | $10.36 | -42.08% | 1 | Nov 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $6 | $5.47 | +9.69% | 2 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $9 → $5 | $0.80 | +524.77% | 3 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $9.12 | +86.40% | 1 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $64 | $26.83 | +138.54% | 2 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $66 → $70 | $18.00 | +288.89% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $29 | $14.76 | +96.48% | 5 | Jul 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $26 | $3.44 | +655.81% | 3 | Jun 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $12 | $33.54 | -64.22% | 2 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $10 | $4.24 | +135.85% | 4 | Apr 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $675 → $400 | $9.58 | +4,075.37% | 2 | Mar 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $80 | $13.83 | +478.45% | 2 | Dec 8, 2020 |
RAPT Therapeutics
Sep 26, 2025
Upgrades: Outperform
Price Target: $16 → $37
Current: $29.34
Upside: +26.11%
Equillium
Mar 28, 2025
Downgrades: Market Perform
Price Target: $3 → $1
Current: $1.46
Upside: -31.51%
Q32 Bio
Dec 11, 2024
Downgrades: Market Perform
Price Target: $68 → $9
Current: $3.17
Upside: +183.91%
Aclaris Therapeutics
Nov 19, 2024
Upgrades: Outperform
Price Target: $2 → $7
Current: $1.90
Upside: +268.42%
Alumis
Jul 23, 2024
Initiates: Outperform
Price Target: $29
Current: $4.49
Upside: +545.88%
Cartesian Therapeutics
Apr 23, 2024
Initiates: Outperform
Price Target: $39
Current: $8.99
Upside: +333.77%
Sagimet Biosciences
Mar 25, 2024
Initiates: Outperform
Price Target: $26
Current: $7.36
Upside: +253.26%
ABIVAX Société Anonyme
Nov 14, 2023
Initiates: Outperform
Price Target: $20
Current: $92.73
Upside: -78.43%
argenx SE
Mar 3, 2023
Maintains: Outperform
Price Target: $430 → $435
Current: $843.66
Upside: -48.44%
Disc Medicine
Feb 28, 2023
Initiates: Outperform
Price Target: $36
Current: $89.94
Upside: -59.97%
Feb 8, 2023
Maintains: Outperform
Price Target: $9 → $7
Current: $1.73
Upside: +304.62%
Feb 6, 2023
Maintains: Outperform
Price Target: $14 → $21
Current: $17.51
Upside: +19.93%
Jan 9, 2023
Maintains: Outperform
Price Target: $40 → $45
Current: $24.21
Upside: +85.87%
Nov 22, 2022
Initiates: Outperform
Price Target: $6
Current: $10.36
Upside: -42.08%
Nov 9, 2022
Maintains: Outperform
Price Target: $5 → $6
Current: $5.47
Upside: +9.69%
Oct 21, 2022
Downgrades: Market Perform
Price Target: $9 → $5
Current: $0.80
Upside: +524.77%
Aug 25, 2022
Initiates: Outperform
Price Target: $17
Current: $9.12
Upside: +86.40%
Aug 9, 2022
Maintains: Outperform
Price Target: $68 → $64
Current: $26.83
Upside: +138.54%
Aug 9, 2022
Maintains: Outperform
Price Target: $66 → $70
Current: $18.00
Upside: +288.89%
Jul 11, 2022
Maintains: Outperform
Price Target: $50 → $29
Current: $14.76
Upside: +96.48%
Jun 1, 2022
Maintains: Outperform
Price Target: $33 → $26
Current: $3.44
Upside: +655.81%
Apr 28, 2022
Maintains: Outperform
Price Target: $18 → $12
Current: $33.54
Upside: -64.22%
Apr 11, 2022
Maintains: Outperform
Price Target: $15 → $10
Current: $4.24
Upside: +135.85%
Mar 16, 2021
Maintains: Outperform
Price Target: $675 → $400
Current: $9.58
Upside: +4,075.37%
Dec 8, 2020
Maintains: Outperform
Price Target: $42 → $80
Current: $13.83
Upside: +478.45%